Introduction
Scientific advances successful knowing the molecular ground of diseases are generating caller and effectual rationally-designed treatments that committedness to amended wellness outcomes. However, wellness systems look expanding challenges to the sustainability of equitable wellness care. Even anterior to the COVID-19 pandemic, wellness expenditure arsenic a fraction of gross home merchandise (GDP) has been rising year-on-year successful each higher-income countries, reaching 17% successful the US and 10.2% successful Australia successful 2019. Costs are rising successful portion owed to the request for wellness attraction by increasing and ageing populations. Drug improvement is simply a large contributor to wellness costs – the mean outgo of getting a caller cause into the marketplace is estimated astatine US$1.3 billion1. Countries specified arsenic the US, the UK, and Australia are tackling the affordability situation by engaging successful risk-sharing agreements with manufacture (also called managed introduction agreements, diligent entree schemes, among different terms)2. Globally, governments and manufacture admit that cardinal changes are indispensable to assistance code the sustainability of wellness care.
This contented is peculiarly pressing for cancer, the starring origin of decease successful higher-income countries. Fundamentally a familial disease, crab attraction is being radically transformed by the duplicate influences of genomic technologies and rational cause development. By 2018, biomarker-dependent drugs accounted for 42% of approvals by the US Food and Drug Administration (FDA) successful 2018, a doubling from 20143. The widening spread betwixt the imaginable of subject to amended health, and its affordability, is exemplified by non-small compartment lung cancer, the starring origin of crab deaths world-wide. There are present 10 molecularly chiseled subtypes of non-small compartment lung crab for which determination are effectual therapies, accounting for much than 50% of each affected patients4. However, lone 3 of these therapies are publically reimbursed successful Australia. The Australian Pharmaceutical Benefits Advisory Committee considers 5 large factors successful their recommendations for caller cause sum and reimbursement5. Clinical interaction comprises lone 1 of these 5 factors, with the remainder concerning cost-effectiveness and budgetary impact.
In March 2022, the Australian authorities announced enactment for a extremist attack to solving this problem, the constitution of a AU$185 cardinal (US$130 million) innovative multi-stakeholder public-private associated task for precision oncology6, whose conceptual model is outlined successful this article. We research the existent inefficiencies successful cause improvement successful single-payer wellness systems (exemplified by Canada, Denmark, Norway, Australia, Taiwan and Sweden) owed to the often adversarial narration betwixt governments and industry. Further, we suggest that affordable diligent entree to wellness attraction is achievable done collaborative engagement betwixt governments and manufacture successful cause development. Although focused connected precision oncology, the ideas outlined present are broadly applicable to the sustainability of science-led transformations successful wellness care.
Drug development: challenges and opportunities
Public and backstage assemblage engagement successful cause improvement tin beryllium conceptualized successful 3 chiseled stages on the worth chain7 (Fig. 1). Stage 1 involves find probe – predominantly funded by authorities and philanthropy, and undertaken successful the nationalist sector. Basic aesculapian probe generates intelligence property, which is licensed oregon sold by world institutions to industry, partially recouping the costs of research. Stage 2 involves the manufacture pursuing precedence cause targets with a absorption connected pb compound recognition and medicinal chemistry, followed by objective trials (phases 1 to 3). Industry funds the wellness assemblage to behaviour trials successful progressively biomarker-selected populations, often wrong hospitals. The nonaccomplishment complaint is high, with 15-35% of drugs reaching signifier 2 trials yet obtaining regulatory approval1. This fig is little for oncology astatine 6.7%. In signifier 3, caller drugs whitethorn go a reimbursed modular of attraction aft policymakers reappraisal for objective inferior and cost-effectiveness successful definite jurisdictions. In single-payer wellness systems, the nationalist assemblage pays manufacture for these drugs, with the terms successful reflecting the full costs of cause improvement (including those that fail), arsenic good arsenic maximizing commercialized returns.
Red arrows picture investments; greenish arrows picture returns; bluish arrows bespeak exchanges of value; yellowish arrows bespeak accusation transfer. Sizes of arrows correspond the comparative magnitude of monetary worth transfer.
This exemplary is characterized by siloing of each signifier from the other, and the usage of wealth arsenic the portion of worth transfer. Each spouse pays for the services oregon goods with the extremity of maximizing monetary gains wrong each stage, and the cumulative outgo rises arsenic cause improvement proceeds from signifier 1 to signifier 3. Considering the interdependent quality of cause development, we contend that the deficiency of integration betwixt wellness assemblage and manufacture contributes to inefficiencies that summation the nett cost.
Stage 2, focussing connected objective trials, is arguably wherever the top interdependence betwixt the nationalist and backstage sectors lies. Much of the full outgo of cause improvement is owed to objective trials8, which are needfully conducted by manufacture successful the discourse of wellness systems. Through progressively analyzable regulatory and governance processes, wellness systems lend to trials inefficiency and costs9,10,11,12. Clinical trials are not considered halfway concern for astir wellness systems. For example, lone 8% of big crab patients enactment successful trials successful Australia13. While wealth is the large portion of worth speech betwixt manufacture and wellness systems, each enactment has further assets of communal involvement that could signifier an alternate ground of worth exchange. The wellness system’s main assets are the patients required for objective trials and the information that is simply a earthy byproduct of wellness attraction delivery. The worth of this information is presently mostly unrealized, though it constitutes the earthy substrate for rational cause improvement and wellness exertion assessment. Industry expends billions connected the instauration of ‘real-world data’ assets14, exemplified by the marketplace capitalization of entities similar Tempus and Flatiron Health15,16. Ironically, manufacture indispensable yet recoup the further costs of generating real-world information from the wellness strategy arsenic portion of the full costs of cause development.
Industry’s main plus of involvement to the wellness strategy are the drugs and different technologies it produces to amended wellness outcomes, presently mostly accessible universally lone successful Stage 3. For industry, the costs of manufacturing drugs are a fraction of the full costs of trials (patient screening, consent, information collection). Nonethless, expanding information successful biomarker-dependent objective trials would accelerate cause development.
Can we conceive a public-private concern successful which the wellness strategy actively supports objective trials arsenic a modular of care, efficaciously realizing the worth of accusation successful speech for aboriginal cause access, portion expanding the wide ratio and decreasing the costs of cause development?
Clinical trials: a caller modular of care?
These concepts person wide exertion successful oncology, wherever advances successful genomics person radically accelerated cause development. It is estimated that, of much than 840 oncology drugs successful improvement successful 2018, >90% are biomarker-dependent17. A biomarker, arsenic defined by FDA and the National Institutes of Health, is simply a “characteristic that is measured arsenic an indicator of mean biologic processes, pathogenic processes, oregon responses to an vulnerability oregon intervention, including therapeutic interventions”18. As noted above, objective trials are not a halfway portion of modular oncology practice. In the 1990s, a signifier 1 survey of a caller chemotherapy offered a debased effect complaint (e.g., 5%) with unquantifiable hazard of toxicities. The concern is changing rapidly. Participation successful a signifier 1 survey of a rationally-designed cause directed astatine a matched biomarker present offers a effect complaint successful excess of 30%19. Consider doxorubicin, a modular of attraction for a diligent with recently diagnosed metastatic sarcoma, with effect rates of betwixt 10% and 30%20,21,22. For patients carrying the applicable biomarker, a signifier 1 survey contiguous appears to connection a amended accidental of effect than the modular of care.
It is important to enactment that trials-based therapies transportation inherently greater uncertainty than standard-of-care treatment, which should beryllium considered successful the pursuing projected model. For this reason, we person focused connected the terminal stages of a crab diligent journey, wherever astir patients tally retired of standard-of-care options. In these circumstances of unmet aesculapian needs, objective trials of biomarker-dependent therapies connection further important options for patients who stay acceptable capable for treatment. Further, we expect that proceedings drugs whitethorn person roles adjacent astatine earlier stages of the crab journey, wherever standard-of-care treatments exist. Participation ethically approved objective trials randomizing caller against standard-of-care crab treatments could connection entree to promising caller therapies. Given the uncertainty attached to the objective benefits of information successful objective trials, it volition beryllium important to show objective outcomes prospectively arsenic portion of the projected model.
Enhanced ratio and reduced costs of biomarker-dependent cause development
If the rule of diligent payment is accepted, does accrued entree to objective trials marque economical sense? The rising costs of caller drugs has fundamentally changed the reply to this question. Let america presume that the wellness strategy bears standard-of-care attraction outgo of $60,000 per diligent per year, specified that the full outgo to the wellness strategy is $600,000 for 10 patients treated (Fig. 2a). If 5 of 10 patients entree a cause provided for escaped by an manufacture spouse done a trial, this provides a attraction cost-offset of $300,000 to the wellness strategy compared to standard-of-care cause entree (Fig. 2b). Effectively, a fraction of the authorities pharmaceutical fund could beryllium partially re-purposed to enactment the enlargement of trials arsenic a modular of care. Even if the wellness strategy was to put an further $5,000 per diligent to enactment genomic screening and information successful objective trials and outgo per diligent treated is $23,300, the strategy would inactive prevention $36,700 per diligent assuming an further 5 radical would enrol and person attraction done trials (Fig. 2c; compared to Fig. 2a, outgo per diligent treated is $60,000). The much radical entree therapies via objective trials, the amended for the economical payment to the wellness system. To incentivize manufacture to behaviour trials, the wellness strategy needs to lend to making trials much efficient. For industry, an businesslike summation successful objective trials information reduces the magnitude of clip to behaviour trials and associated costs.
©[Leremy Gan] via Canva.com. a: existent modular of attraction treatment; b: objective trials-based care; c: expanded objective trials supported by population-level screening.
For oncology cause development, wellness system-industry collaboration offers galore opportunities for efficiencies and outgo savings. Oncology drugs progressively people biomarkers, often successful the signifier of mutations detectable by genomic screening. Cancers are being progressively subdivided therapeutically according to these biomarkers, generating the request to place circumstantial subpopulations carrying the cognate therapeutic biomarker for objective trials. The outgo of screening ample numbers of patients to find these subgroups adds to the costs of cause development. A applicable cause people whitethorn beryllium contiguous successful less than 1% of the wide population, meaning that 100 radical request to beryllium screened to find 1 eligible participant. Currently, manufacture bears the costs of identifying specified patients for objective trials done diagnostic screening tests, astir invariably focusing connected a azygous cistron target, conducted separately for each proceedings and participating institution. Typically these azygous cistron tests bespeak the regulatory bodies’ request that a purpose-built companion diagnostic beryllium approved with the therapy – a co-dependent technology.
The advent of broad genomic profiling (CGP) tin radically alteration the ratio of identifying subpopulations for objective trials. CGP enables the screening of hundreds of imaginable cause targets successful a azygous assay23,24, specified that 1 trial could beryllium utilized to triage patients for dozens of trials. Realising the efficiencies of this attack requires the displacement from trial-specific azygous cistron testing, to CGP screening of diligent populations connected behalf of aggregate trials.
To exemplify this, see the pursuing hypothetical illustration of 10 companies intending to execute 10 trials (Fig. 3). Each proceedings is babelike connected screening for a chiseled biomarker contiguous successful the colonisation astatine a 1% frequency. Each proceedings needs to surface 2,000 patients to place 20 patients with the applicable biomarker (assuming for the purposes of statement 100% enrolment of suitable candidates onto each trial). Using a diagnostic screening trial that costs $500 per individual, a 20-patient proceedings requires a $1 cardinal screening fund (Fig. 3a). For a proceedings that costs $1 cardinal to tally (20 patients x $50,000 per diligent enrolled), screening whitethorn relationship for fractional of the full cost. Collectively, 10 trials request to surface 20,000 patients utilizing 10 biomarker-specific and purpose-built tests, with full screening expenditure of $10 million.
©[Pixeden] via Canva.com.
However, if the 10 biomarkers for these trials are mutually exclusive, past successful rule lone 2000 patients request to beryllium screened to enactment each 10 trials done a azygous CGP trial (Fig. 3b). If a CGP trial costs $2500 per individual, screening 2000 individuals would outgo $5 cardinal to enactment 10 trials. Alternatively, utilizing the archetypal $10 cardinal fund for each 10 trials, 4000 patients could beryllium screened, identifying those patients doubly arsenic fast, thereby cutting the clip to proceedings completion by half. In summary, the reduced costs of identifying eligible patients, and the acceleration of trials completion, are the duplicate drivers for decreasing the costs of cause development. Furthermore, CGP outgo is declining, making population-level screening for guiding cause treatments much feasible.
Screening for 10 trials involving aggregate manufacture partners, requires an ‘honest broker’ operating connected behalf of each parties, with entree to the diligent populations to beryllium screened. For these reasons, wellness systems, either straight oregon via an ‘honest broker’, are ideally placed to undertake biomarker screening successful concern with industry. The backing for CGP tests whitethorn beryllium cost-efficient for wellness systems arsenic patients mightiness displacement from system-reimbursed therapy to trial-based therapy.
The collaborative exemplary has an important further payment by expanding screening from sites wherever trials are conducted, to a overmuch larger colonisation crossed the full wellness strategy (Fig. 4). Screening is constricted to proceedings sites successful the accepted model. The sponsor needs to unfastened much proceedings sites to maximise the colonisation to beryllium screened due to the fact that of the diligent catchment country of the institution. If sites bash not routinely undertake screening, this is funded by each trial. Opening each proceedings tract adds costs and clip related to governance and monitoring complexities. In contrast, the collaborative exemplary would request less proceedings sites since the fig of proceedings sites is predicated connected the tract proceedings capacity, not its diligent catchment. To exemplify this point, for uncommon crab populations, trials whitethorn not beryllium feasible if the sponsor opens proceedings sites astatine 12 institutions to place 22 patients for a trial, missing the accidental of recruiting 28 radical who are extracurricular the proceedings sites (Fig. 4a). On the different hand, each 50 radical could beryllium identified by an autarkic population-based screening programme successful the collaborative model, who are referred to lone 4 sites opened for proceedings conduct, expanding proceedings ratio (Fig. 4b). This increases the objective acquisition astatine each site, and the publication of tract investigators successful answering the proceedings question. It besides increases the strategy capableness for trials successful total, by distributing the load of proceedings behaviour crossed a broader scope of treating centres, whereas presently the load of trials falls asymmetrically connected high-volume centres, whose capableness whitethorn beryllium saturated. Finally, it increases objective trials engagement of centres which mightiness different not enactment owed to their diligent volumes. Some of the outgo savings outlined supra could beryllium reallocated to subsidies to enactment diligent question crossed a broader web of proceedings centres.
a Screening and proceedings sites for objective trials by model. The numbers supra each instauration correspond eligible patients for a biomarker babelike trial. b Differences successful ratio for proceedings recruitment betwixt models. ©[Visual Generation, Pixeden] via Canva.com.
Importantly, the collaborative exemplary volition pb to amended wellness outcomes for patients overall, for respective reasons: (1) the full fig of patients receiving biomarker-dependent therapies should summation compared with the existing model, owed to enhanced entree to trials; (2) the greater ratio of CGP screening means that a greater fraction of patients carrying the applicable treatable biomarker volition beryllium identified than is presently the case; and (3) the greater velocity and ratio of trials behaviour volition trim the nett costs of cause development. In short, the greater the fig of trials, the greater the amortization of the costs of CGP screening (or the greater the numbers of patients that tin beryllium screened with the aforesaid resource).
Structural considerations
The interface betwixt wellness systems and manufacture indispensable instrumentality into relationship respective considerations. Health systems are not well-designed for nonstop engagement with industry. The entrepreneurial attack important to a palmy concern with manufacture is not a communal diagnostic of bureaucracies. To date, precision medicine has typically been funded utilizing comparatively short-term, project-based probe funding, which are usually constricted successful standard and bash not see semipermanent sustainability. Moreover, determination are bully reasons to clasp immoderate grade of independency of authorities from industry, recognizing the competing interests betwixt the economic, health, national extortion and regulatory functions of authorities successful cause development. Finally, successful immoderate wellness systems, determination is adaptable alignment betwixt national and authorities oregon provincial governments. In Australia, though precision medicine constitutes a substance of nationalist interest, it is delivered done infirmary networks chiefly funded by state/territory governments. A akin exemplary besides exists successful Canada. Integrating the interests and roles of some national and state/territory governments has been a structural impediment to nationally accordant wellness care.
A solution to these requirements is being tested successful Australia is the instauration of a non-profit institution (Omico) with some authorities and Federal authorities funding, which has developed a associated task model for co-investment with manufacture successful a nationalist precision oncology platform6. Omico provides a stable, nationalist ‘honest broker’ relation connected behalf of the wellness strategy with the taste and ineligible state to make innovative, collaborative engagement betwixt manufacture and the wellness system. In practice, Omico commissions biomarker screening for referred patients, and returns a study to the referring clinician, who past decides whether the recommended objective proceedings is due for their patient. We enactment that the projected collaborative exemplary has exertion beyond crab to each wellness conditions relying connected biomarker-dependent cause improvement (e.g., cardiovascular, renal, endocrine).
Economic benefits
In summation to amended wellness care, determination are economical benefits to greater engagement betwixt the nationalist assemblage and industry. Health is typically seen arsenic an ‘expenditure’ portfolio for the government. The pharmaceutical manufacture generates gross successful excess of US$1.25 trillion globally, increasing astatine 5% per annum25. For a colonisation of 25 million, the Australian pharmaceutical manufacture contributes much than AU$8.9 cardinal (US$6.3 billion) annually to the economy, and supports astir 23,000 full-time jobs26. Cancer objective trials unsocial lend implicit AU$1 cardinal (US$0.7 billion) annually to the Australian economy, supporting astir 7,000 highly skilled jobs26. Investments successful the beingness sciences assemblage generates economical growth, jobs successful education, training, infrastructure and enactment roles, stimulating commercialization of aesculapian probe done accelerated section biomarker-dependent cause development, and enhancing greater engagement with planetary pharmaceutical industry. These outcomes represent strategical goals communal to the wellness strategy and economy, the world sector, and industry.
There are evident challenges to the occurrence of public-private partnerships that see societal and ineligible issues, governmental will, bureaucratic inertia, and morganatic competing interests. Social and ineligible issues subordinate to privateness concerns and commercialisation of wellness data. This is partially owed to the cognition of antagonistic interests of manufacture and citizens, and partially owed to perceptions of probe arsenic irrelevant to wellness care. Disengagement of the nationalist assemblage from manufacture leaves patients without entree to drugs, and nine with less options for economical growth. At the different extreme, a afloat privatised healthcare exemplary whitethorn compromise semipermanent societal value. Tempo besides contributes to the challenges: the debased hazard appetite of wellness systems leads to structural and taste conservativism, portion probe has an inherently greater hazard appetite. The question is whether the hazard appetite of wellness systems tin beryllium adjusted to payment patients who are dying from treatable diseases.
Future directions
The exemplary projected ambitiously advocates for objective trials arsenic a modular of care. Due to the inherent objective and economical uncertainties, we person projected that it should beryllium implemented initially for patients who person exhausted accepted attraction options. However, the exemplary could use astatine each stages of the crab journey, wherever information successful randomised objective trials could beryllium a standard-of-care. This attack would necessitate capable grounds from earlier signifier investigating to ethically warrant randomisation betwixt existing and caller treatments. Biomarker screening is besides evolving rapidly. Beyond broad genomic panels, full genome and transcriptome sequencing approaches are being evaluated, and connection imaginable advantages27. While regular pathology processing and costs marque focused panels much applicable currently, the exertion is rapidly evolving and costs of full genome sequencing are falling, and regular signifier volition apt accommodate implicit time. One much wide payment of integration of probe into standard-of-care is to accommodate blimpish wellness systems to align amended with the accelerating gait of technological development. Notably, determination are therapeutic biomarkers beyond genomics (DNA and RNA), including proteomics and the microbiome, that are transforming crab objective probe and care. At the strategy level, a data-driven attack is intelligibly important to optimising the integration of probe into standard-of-care effectively, equitably, and sustainably.
The expanding faction of GDP owed to wellness expenditure world-wide is driven by the inexhaustible societal appetite for amended wellness outcomes and the successes of science. Recent acquisition with COVID-19 and HIV person shown that subject is captious to solving wellness crises successful real-time, and reinforced the hostility betwixt wellness and the economy. The situation successful semipermanent affordability of wellness attraction is exacerbated by aging populations and comparative diminution of payer basal backing wellness care. Two conclusions are clear: (1) the rate-limiting measurement successful realising these outcomes is nary longer scientific, but lies successful our wellness system’s quality to integrate subject into wellness care; and (2) the nationalist and backstage sectors person complementary roles successful delivering the benefits of subject to mankind. Like clime change, wellness attraction is excessively important to nine to beryllium near either to the nationalist oregon backstage sectors alone, and tin lone beryllium addressed successful partnership.
Data availability
not relevant.
Code availability
not relevant.
References
Wouters, O. J., McKee, M. & Luyten, J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA 323, 844–853 (2020).
Garrison, L. P. et al. Private assemblage risk-sharing agreements successful the United States: trends, barriers, and prospects. Am. J. Manag Care 21, 632–640 (2015).
Personalized Medicine Coalition. Personalized Medicine astatine FDA: A Progress & Outlook Report. https://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PM_at_FDA_A_Progress_and_Outlook_Report.pdf, (2018).
Mateo, J. et al. Delivering precision oncology to patients with cancer. Nat. Med 28, 658–665 (2022).
Australian Government Department of Health and Aged Care. The Pharmaceutical Benefits Advisory Committee Guidelines. https://pbac.pbs.gov.au/information/about-the-guidelines.html, (2016).
Garvan Institute of Medical Research. $185 cardinal concern to fast-track treatments for uncommon and ‘untreatable’ cancers. https://www.garvan.org.au/news-events/news/185-million-investment-to-fast-track-treatments-for-rare-and-2018untreatable2019-cancers, (2022).
Kim, S. Y. & Rosendorff, B. P. Firms, states, and planetary production. Econ. Politics 33, 405–414 (2021).
Moore, T. J., Zhang, H., Anderson, G. & Alexander, G. C. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. JAMA Intern. Med. 178, 1451–1457 (2018).
Kantarjian, H. M., Fojo, T., Mathisen, M. & Zwelling, L. A. Cancer drugs successful the United States: Justum Pretium-the conscionable price. J. Clin. Oncol. 31, 3600–3604 (2013).
Kantarjian, H. & Zwelling, L. Cancer cause prices and the free-market forces. Cancer 119, 3903–3905 (2013).
Kantarjian, H. et al. High crab cause prices successful the United States: reasons and projected solutions. J. Oncol. Pr. 10, e208–211, https://doi.org/10.1200/JOP.2013.00135, (2014).
Steensma, D. P. & Kantarjian, H. M. Impact of crab probe bureaucracy connected innovation, costs, and diligent care. J. Clin. Oncol. 32, 376–378 (2014).
Unger, J. M., Vaidya, R., Hershman, D. L., Minasian, L. M. & Fleury, M. E. Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. JNCI: J. Natl Cancer Inst. 111, 245–255 (2019).
Sherman, R. E. et al. Real-World Evidence - What Is It and What Can It Tell Us? N. Engl. J. Med 375, 2293–2297 (2016).
Fernandes, L. E. et al. Real-world Evidence of Diagnostic Testing and Treatment Patterns successful US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data. Clin. Breast Cancer 21, e340–e361 (2021).
Khozin, S. et al. Real-world progression, treatment, and endurance outcomes during accelerated adoption of immunotherapy for precocious non-small compartment lung cancer. Cancer 125, 4019–4032 (2019).
The IQVIA Institute. Global Oncology Trends 2018. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2018, (2018)
Hayes, D. F. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician’s Viewpoint. J. Clin. Oncol. 39, 238–248 (2021).
Schwaederle, M. et al. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival successful Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2, 1452–1459 (2016).
Santoro, A. et al. Doxorubicin versus CYVADIC versus doxorubicin positive ifosfamide successful first-line attraction of precocious brushed insubstantial sarcomas: a randomized survey of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 13, 1537–1545 (1995).
Edmonson, J. H. et al. Randomized examination of doxorubicin unsocial versus ifosfamide positive doxorubicin oregon mitomycin, doxorubicin, and cisplatin against precocious brushed insubstantial sarcomas. J. Clin. Oncol. 11, 1269–1275 (1993).
Cruz, A. B. et al. Combination chemotherapy for soft-tissue sarcomas: a signifier III study. J. Surg. Oncol. 11, 313–323 (1979).
Beaubier, N. et al. Integrated genomic profiling expands objective options for patients with cancer. Nat. Biotechnol. 37, 1351–1360 (2019).
Cheng, M. L., Berger, M. F., Hyman, D. M. & Solit, D. B. Clinical tumour sequencing for precision oncology: clip for a cosmopolitan strategy. Nat. Rev. Cancer 18, 527–528 (2018).
Statista. Global pharmaceutical marketplace size 2001-2021. https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/, (2022)
Medical Technologies and Pharmaceuticals Industry Innovation Growth Centre. Clinical Trials successful Austalia: The Economic Profile and Competitive Advantage of the Sector. https://www.mtpconnect.org.au/images/MTPConnect%202017%20Clinical%20Trials%20in%20Australia%20Report.pdf.pdf, (2017).
Samsom, K. G. et al. Feasibility of whole-genome sequencing-based tumor diagnostics successful regular pathology practice. J. Pathol. 258, 179–188 (2022).
Acknowledgements
We are grateful to Alyssa Halbisen, BS, Harvard Pilgrim Health Care Institute, for her administrative support. We besides privation to convey our galore colleagues who person contributed to discussions that gave emergence to the ideas successful this paper. This commentary did not person funding.
Ethics declarations
Competing interests
DMT is the CEO of Omico, a non-profit precision oncology program. He has received probe enactment arsenic good arsenic honoraria and speakers bureau from Astra Zeneca, Roche, Pfizer, Novartis, Eisai, Beigene, Seattle Genetics, Janssen, Bayer, Microba, InterVenn, Merck. VT is lawman CEO of Omico. The remaining authors state nary competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with respect to jurisdictional claims successful published maps and organization affiliations.
Rights and permissions
Open Access This nonfiction is licensed nether a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, organisation and reproduction successful immoderate mean oregon format, arsenic agelong arsenic you springiness due recognition to the archetypal author(s) and the source, supply a nexus to the Creative Commons license, and bespeak if changes were made. The images oregon different 3rd enactment worldly successful this nonfiction are included successful the article’s Creative Commons license, unless indicated different successful a recognition enactment to the material. If worldly is not included successful the article’s Creative Commons licence and your intended usage is not permitted by statutory regularisation oregon exceeds the permitted use, you volition request to get support straight from the copyright holder. To presumption a transcript of this license, sojourn http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lu, C.Y., Terry, V. & Thomas, D.M. Precision medicine: affording the successes of science. npj Precis. Onc. 7, 3 (2023). https://doi.org/10.1038/s41698-022-00343-y
Received: 24 July 2022
Accepted: 21 December 2022
Published: 04 January 2023
DOI: https://doi.org/10.1038/s41698-022-00343-y
English (US)